Press Release AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies Aug 27
Press Release AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171 Aug 3